Investor Relations & Capital Markets

Transcription

1 Investor Relations & Capital Markets

2 Contents Financial Review Operational Review A New Scope: Toiletries Ownership Appendices 2

3 Focused on Profitability... (TRL in millions except EPS) As of June 30, Chg Revenues 2, , % Gross Income % Gross Margin 8.08% 9.51% pts EBITDA % EBITDA Margin 3.16% 4.50% pts Net Income % Net Income Margin 2.91% 3.38% pts EPS % 3

4 We have a track record of strong revenue growth... TL Billions 8% CAGR 2,54 2,41 2,60 2,50 2,59 1,50 1,82 1, /6 2007/6 2008/6 2009/6 2010/6 2011/6 2012/6 2013/6 4

5 ...that we have leveraged into higher income TL millions 15% CAGR 119,56 84,90 74,14 97,61 72,02 83,63 75,33 28, /6 2007/6 2008/6 2009/6 2010/6 2011/6 2012/6 2013/6 5

6 Working Capital Management mn. FY06 FY07 FY08 FY09 FY10 FY11 FY12 1Q13 A/R 1,209 1,303 1,502 1,538 1,538 1,538 1,571 1,661 Inventories A/P 929 1,043 1,234 1,228 1,362 1,325 1,342 1,418 WC WC/Sales (%)

7 OpEx Improvement FY06 FY07 FY08 FY09 FY10 FY11 FY12 2Q13 Revenue (mn.) 3,151 3,628 4,047 5,029 4,902 5,074 4,902 2,587 # of WHs # of Employees 4,694 4,554 4,600 4,893 5,162 5,322 5,049 5,017 OpEx / Sales 4.84% 4.49% 4.57% 3.93% 4.28% 4.74% 5.37% 5.36% Personnel / Sales 2.86% 2.69% 2.64% 2.39% 2.66% 2.79% 3.23% 3.09% Employee per WH Revenue per Employee 671, , ,676 1,027, , , , ,601 7

8 OpEx Breakdown OPERATIONAL EXPENSES 20132Q % 20122Q % 2013 vs Personnel expense 80,050, % 76,696, % 4.37% Health sector fair expenses 9,546, % 5,275, % 80.95% Fuel expense 10,646, % 10,448, % 1.89% Transportation expense 6,822, % 6,324, % 7.88% Depreciation expense 5,976, % 5,659, % 5.60% Outsourced benefits and services 4,792, % 6,188, % % Other 3,805, % 5,411, % % Insurance expense 2,918, % 2,258, % 29.25% Repair and maintenance expense of motor vehicles 2,808, % 3,002, % -6.49% Rent expense 2,747, % 3,471, % % Communication expense 2,377, % 2,366, % 0.47% Tax expense 1,653, % 1,056, % 56.48% Donations and aids 1,670, % 2,630, % % Stationery expense 1,210, % 1,335, % -9.38% Promotion expenses 465, % 719, % % Representation and host expenses 984, % 794, % 23.85% Advisory and audit fees 230, % 231, % -0.50% Total 138,705, ,871, % 8

9 Contents Financial Review Operational Review A New Scope: Toiletries Ownership Appendices 9

10 Sustainable growth to Market Leader Position... Market Share (%) 33,40% 34,40% 36,09% 35,41% 35,69% 34,40% 34,71% Q 10

11 A progressive network across the Country by over 100 warehouses Main Regional Warehouses Warehouses Total Selçuk Ecza As Ecza Group Total

12 Operational Stats I 12

13 Operational Stats II 13

14 Contents Financial Review Operational Review A New Scope: Toiletries Ownership Appendices 14

15 Toiletry Segment: A significant catalyst... Selcuk Ecza has started to sell/distribute toiletry products (personal care products, cosmetics etc.) by June 1, 2009 and expanded it to all of its warehouses Using the same distribution network, while by using the avalaible spare capacity in warehouses lead to an insignificant increase in CAPEX The market size in Turkey for toiletry products is approximately as of US$11 bn. And almost US$1 bn. of it is pharmacies share Strategy to create a steady amount of additional revenue from this segment in order to support a sustainable profit level Higher gross margin around 10-11% compared to 7-8% from pharma segment Selcuk Ecza generated 265 mn. TRL in FY11 and 375 mn. in FY12 for this segment, while medium term target is 500 mn TRL as of app. 10% of available topline. 15

16 Contents Financial Review Operational Review A New Scope: Toiletries Ownership Appendices 16

17 Ownership Ahmet & Nezahat Kelesoglu Foundation (51%) Ahmet Kelesoglu (39.20%) Nezahat Kelesoglu (9.80%) x = 7.58% Selcuk Ecza Holding A.S. Free Float* Gurgen Family x = 30.31% 77.32% 20.01% 2.67% 0.51x = 39.43% Selcuk Ecza Deposu Ticaret ve Sanayi A.S. *Selcuk Ecza Holding A.S. acquired 5% of free float, total % of ownership increased to 82, % As Ecza 17

18 Selcuk Ecza: A precious link to sustainable value creation Attractive markets Demographics drive long-term demand Public policy agenda supports greater access and improved efficiency Well-positioned businesses Solid operating profit and cash flow strength from distribution segment Nationwide network built over mutual commercial interests Steady track record of delivering results and a balanced approach to capital deployment Strong balance sheet and solid liquidity position Experienced and tenured management team 18

19 Contents Appendices Appendix-1: Reimbursement Schedule Appendix-2: Reference Pricing Scheme Appendix-3: The New Regulation Appendix-4: Summary Financials: Income Statement & Balance Sheet 19

20 Appendix-1: Reimbursement Schedule REIMBURSEMENT to PHARMACIES by THE SSI Dispensing Application to SSI Reimbursement First Day of Month Average 15 Days Last Day of Month 15 Days 15th of the Following Month Max 60 Days 20

21 Appendix-2: Reference Pricing Scheme Reference Countries France Italy Spain Portugal Greece 100% = Brands Price (If its generic does not exist in the market) 60% = Brands Price (If its generic exists in the market) 60% = Generic Price *The government has changed the regulation on the reference pricing mechanism and lowered the ratio of both brands and generics to 60% of the reference price on Nov.10, 2011 which is valid since Nov.18, ** The government recently lowered the price ceiling from 15% to 10% for the reimbursement price of generic drugs in the same bioequivalance group (which is applied over the lowest price of the generic product in the market; the lower 10% limit came into force from Nov. 5, 2011). REIMBURSEMENT Generic Drugs in the Same Bioequivalence Group p t j y z q x n % higher than the cheapest price* p & n NOT reimbursed 21

22 Appendix-3: Major Regulatory Items as of Nov The price ceiling for branded drugs has been reduced to 60% from 66% of the reference price, which is determined according to lowest price in the five reference EU member countries (France, Italy, Spain, Portugal, Greece), if the branded drug has a generic substitute available in the market, although the price ceiling remained at 100% for branded drugs that do not have generic substitutes. The price ceiling for generics has been also decreased from 66% to 60% of the reference price. The drugs which stay on the market more than 20 years and with a wholesaler price higher than TRL 6.79, shall be priced at most 80% of its reference price while their generics shall not be priced higher than their branded ones wholesaler prices. All drugs with prices lower than TRL3.56, OTC drugs (without prescription), blood products, infant food, radiopharmaceutical products, enteral feeding products, and all other products that are not stated in public reimbursement list shall not be priced according to this new regulation. The exchange rate mechanism used to determine drug prices has also been changed. According to the new mechanism, the exchange rate may only be revised if the 90-day moving average of EUR/TRL exchange rate exceeds/falls below the periodic EURO value band by +/-5%; while the upper end of this band is estimated as 10% higher of the EUR/TRL exchange rate in effect for calculation of drug prices. (The official EUR/TRL rate is since April 2009) The Notice period for amending the Reference Countries List by the MoH has been reduced from 4 months to 2 months. 22

23 Appendix-4: Summary Financials: Income Statement-Consolidated Income Statement (TL Million) Mar. 31, 2013 Mar. 31, vs Net Sales 2.586, ,96 3,80% Cost of sales (-) (2.377,55) (2.254,97) 5,44% GROSS PROFIT 209,02 236,99-11,80% OPEX (138,71) (135,27) 2,54% Other operating income/exp.(net) 15,28 0, ,69% OPERATING PROFIT 85,59 102,23-16,28% Income/Expense from investment 37,82 7,78 386,26% Finance income /Exp.(Net) (28,84) (5,19) 455,96% EBIT 75,67 106,57-29,00% EBIT (exc.other) 70,31 101,72-30,88% Income before minority Int.& Tax 94,57 104,82-9,78% Minority interest 0,00 0,00-16,97% Income tax expense (19,24) (20,56) -6,44% Net Income / (Loss) 75,33 84,26-10,60% EBITDA 81,64 112,23-27,25% EBITDA (exc.other) 76,29 107,38-28,96% Gross Margin 8,08% 9,51% EBIT Margin 2,93% 4,28% EBIT Margin (exc.other) 2,72% 4,08% EBITDA Margin 3,16% 4,50% 23

24 (TL million) Appendix-4: Summary Financials: Balance Sheet Balance Sheet Cash and cash equivalents Assets June 30, 2013 Dec. 31, 2012 Liabilities & Equity June 30, 2013 Dec. 31, 2012 Accounts rec.& due from related parties Inventories Other current assets Total Current Assets 1, , , , PP&E Short-term debt Accounts payable & due to related parties 1, , Provisions & other current liabilities Total Current Liabilities 2, , , , Long-term debt Provision for Employee Benefits & Other Liabilities Intangible Assets(Including Goodwill) Other non-current assets Deferred tax assets Total Non-Current Assets Total Assets Deferred tax liability Other liabilities Total Non-Current Liabilities Shareholder's equity & minority interest 1, , , , Total Liabilities & Equity 3, ,

25 Selcuk Ecza Deposu A.S. Investor Relations & Capital Markets Istanbul Stock Exchange: SELEC.IS Tel: Bloomberg: SELEC.TI Tel: Fax: Reuters: SELEC.IS